OCEANS: Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer Last updated on Sep 22, 2026 Previous MITO 16B: Bevacizumab Maintenance with Platinum Doublets in Platinum-Sensitive Recurrence Next Platinum Sensitive Recurrent Ovarian Cancer
